OSTEOPOROSIS ASSOCIATED MARKERS AND METHODS OF USE THEREOF
Disclosed are methods of identifying subjects with osteoporosis or osteopenia, subjects at risk for developing osteoporosis, osteopenia, and bone fractures, methods of evaluating the effectiveness of osteoporosis treatments in subjects with osteoporosis or osteopenia, and methods of selecting therapies for treating osteoporosis or osteopenia, using biomarkers.
1 . A method with a predetermined level of predictability for assessing a risk of development of osteoporosis, pre-osteoporosis, or bone fracture in a subject comprising:
a. measuring the level of an effective amount of one or more OSTEORISKMARKERS selected from the group consisting of OSTEORISKMARKERS 1-191 in a sample from the subject, and
b. measuring a clinically significant alteration in the level of the one or more OSTEORISKMARKERS in the sample, wherein the alteration indicates an increased risk of developing osteoporosis, pre-osteoporosis, or bone fracture in the subject.
2 .- 13 . (canceled)
14 . A method with a predetermined level of predictability for diagnosing or identifying a subject having osteoporosis or pre-osteoporosis comprising:
a. measuring the level of an effective amount of one or more OSTEORISKMARKERS selected from the group consisting of OSTEORISKMARKERS 1-191 in a sample from the subject, and
b. comparing the level of the effective amount of the one or more OSTEORISKMARKERS to a reference value.
15 .- 17 . (canceled)
18 . A method with a predetermined level of predictability for assessing the progression of osteoporosis or pre-osteoporosis in a subject, comprising:
a. detecting the level of an effective amount of one or more OSTEORISKMARKERS selected from the group consisting of OSTEORISKMARKERS 1-191 in a first sample from the subject at a first period of time;
b. optionally detecting the level of an effective amount of one or more OSTEORISKMARKERS in a second sample from the subject at a second period of time;
c. comparing the level of the effective amount of the one or more OSTEORISKMARKERS detected in step (a) to the amount detected in step (b), or to a reference value.
19 .- 25 . (canceled)
26 . A method with a predetermined level of predictability for assessing the progression of diminished bone mass associated with osteoporosis or pre-osteoporosis in a subject comprising:
a. detecting the level of an effective amount of one or more OSTEORISKMARKERS selected from the group consisting of OSTEORISKMARKERS 1-191 in a first sample from the subject at a first period of time;
b. optionally detecting the level of an effective amount of one or more OSTEORISKMARKERS in a second sample from the subject at a second period of time;
c. comparing the level of the effective amount of the one or more OSTEORISKMARKERS detected in step (a) to the amount detected in step (b), or to a reference value.
27 .- 33 . (canceled)
34 . A method with a predetermined level of predictability for monitoring the effectiveness of treatment for osteoporosis or pre-osteoporosis in a subject comprising:
a. detecting the level of an effective amount of one or more OSTEORISKMARKERS selected from the group consisting of OSTEORISKMARKERS 1-191 in a first sample from the subject at a first period of time;
b. optionally detecting the level of an effective amount of one or more OSTEORISKMARKERS in a second sample from the subject at a second period of time;
c. comparing the level of the effective amount of the one or more OSTEORISKMARKERS detected in step (a) to the amount detected in step (b), or to a reference value, wherein the effectiveness of treatment is monitored by a change in the level of the effective amount of one or more OSTEORISKMARKERS from the subject.
35 .- 42 . (canceled)
43 . A method with a predetermined level of predictability for selecting a treatment regimen for a subject diagnosed with or at risk for osteoporosis or pre-osteoporosis comprising:
a. detecting the level of an effective amount of one or more OSTEORISKMARKERS selected from the group consisting of OSTEORISKMARKERS 1-191 in a first sample from the subject at a first period of time;
b. optionally detecting the level of an effective amount of one or more OSTEORISKMARKERS in a second sample from the subject at a second period of time;
c. comparing the level of the effective amount of the one or more OSTEORISKMARKERS detected in step (a) to a reference value, or optionally, to the amount detected in step (b).
44 .- 52 . (canceled)
53 . An osteoporosis or pre-osteoporosis reference molecular profile, comprising a pattern of marker levels of an effective amount of one or more markers selected from the group consisting of OSTEORISKMARKERS 1-191, taken from one or more subjects who do not have osteoporosis or pre-osteoporosis.
54 . An osteoporosis or pre-osteoporosis subject molecular profile, comprising a pattern of marker levels of an effective amount of one or more markers selected from the group consisting of OSTEORISKMARKERS 1-191 taken from one or more subjects who have osteoporosis or pre-osteoporosis, are at risk for developing osteoporosis or pre-osteoporosis, or are being treated for osteoporosis or pre-osteoporosis.
55 .- 59 . (canceled)
60 . An OSTEORISKMARKER panel comprising one or more OSTEORISKMARKERS that are indicative of one or more physiological functions or canonical molecular pathways associated with osteoporosis or pre-osteoporosis.
61 .- 69 . (canceled)
70 . An OSTEORISKMARKER panel comprising one or more OSTEORISKMARKERS selected from at least one cluster of OSTEORISKMARKERS defined by the relative proximity of each OSTEORISKMARKER to other cluster member OSTEORISKMARKERS in and across canonical molecular pathways or by the relative correlation of each OSTEORISKMARKER with other cluster member OSTEORISKMARKERS.
71 .- 73 . (canceled)
74 . A method for treating one or more subjects at risk for developing osteoporosis or pre-osteoporosis, comprising:
a. detecting the presence of increased levels of one or more OSTEORISKMARKERS present in a sample from the one or more subjects; and
b. treating the one or more subjects with one or more bone mineral content-modulating drugs until altered levels of the one or more OSTEORISKMARKERS return to a baseline value measured in one or more subjects at low risk for developing osteoporosis or pre-osteoporosis, or a baseline value measured in one or more subjects who show improvements in osteoporosis or pre-osteoporosis risk markers as a result of treatment with one or more bone mineral content-modulating drugs.
75 .- 79 . (canceled)
80 . A method of evaluating changes in the risk of bone fracture or diminished bone mass in a subject diagnosed with or at risk for developing pre-osteoporosis, comprising:
a. detecting the level of an effective amount of one or more OSTEORISKMARKERS selected from the group consisting of OSTEORISKMARKERS 1-191 in a first sample from the subject at a first period of time;
b. optionally detecting the level of an effective amount of one or more OSTEORISKMARKERS in a second sample from the subject at a second period of time;
c. comparing the level of the effective amount of the one or more OSTEORISKMARKERS detected in step (a) to a reference value, or optionally, the amount in step (b).
81 .- 93 . (canceled)
94 . In a method of diagnosing or identifying a subject at risk for developing osteoporosis or pre-osteoporosis by analyzing osteoporosis or pre-osteoporosis risk factors, the improvement comprising:
a. measuring the level of an effective amount of one or more OSTEORISKMARKERS selected from the group consisting of OSTEORISKMARKERS 1-191 in a sample from the subject, and
b. measuring a clinically significant alteration in the level of the one or more OSTEORISKMARKERS in the sample, wherein the alteration indicates an increased risk of developing osteoporosis or pre-osteoporosis in the subject.
95 .- 96 . (canceled)